electroCore,

electroCore, CROIC

The Cash Return on Invested Capital (CROIC) of electroCore, (ECOR) as of Oct 18, 2026 is -107.27 %. In the previous year, Cash Return on Invested Capital (CROIC) was -59.49 % — a change of 80.32% (lower).

CROIC

-107.27 %

YoY

80.32%

Last updated:

Cash Return on Invested Capital (CROIC) of electroCore, is 2025 -107.27 % . Cash Return on Invested Capital (CROIC) of electroCore, was 2024 -59.49 % . It decreases by 80.32% lower compared to the previous year.

The electroCore, CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-72.29 USD
Jan 1, 2019
-171.75 USD
Jan 1, 2020
-77.60 USD
Jan 1, 2021
-36.43 USD
Jan 1, 2022
-93.59 USD
Jan 1, 2023
-184.36 USD
Jan 1, 2024
-59.49 USD
Jan 1, 2025
-107.27 USD
The electroCore, CROIC history
YEARCROICYoY
-107.27 %+80.32%
-59.49 %-67.73%
-184.36 %+96.98%
-93.59 %+156.92%
-36.43 %-53.06%
-77.60 %-54.82%
-171.75 %+137.57%
-72.29 %-355.54%
28.29 %+13.60%
24.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Cash Return on Invested Capital (CROIC) of electroCore, is -107.27 % in 2025.

Cash Return on Invested Capital (CROIC) of electroCore, changed from -59.49 % to -107.27 %, representing a 80.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) electroCore, since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s electroCore, with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — electroCore,

All Key Metrics — electroCore,